Analyst Maintains Buy Rating and $1.50 Price Target on Scienture Amid Strong Early Commercialization for Arbli and Rezenopy
I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Naz Rahman maintained a Buy rating and $1.50 price target on Scienture Holdings, citing strong early commercialization metrics for products Arbli and Rezenopy. Arbli generated $344K in Q2 revenue with broad formulary access, while Rezenopy shipments are expected to contribute revenue in Q3. Management projects operating profitability by 2027 using existing cash.
Naz Rahman, an analyst from Maxim Group, reiterated the Buy rating on Scienture Holdings. The associated price target remains the same with $1.50.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Naz Rahman has given his Buy rating due to a combination of factors, primarily the stronger‑than‑expected early commercialization metrics for Scienture’s lead products. Arbli’s launch is showing meaningful traction, with second‑quarter revenue of $344K versus no material sales previously anticipated, supported by growing prescriptions, broad formulary access exceeding 100M covered lives, and high prior‑authorization approval rates.
Rahman also points to the upcoming revenue contribution from Rezenopy, which has begun initial shipments and should start to be recognized in the third quarter, adding a second commercial growth stream. In addition, management’s view that existing cash and receivables can carry the company to operating profitability by 2027, combined with the niche, under‑served dysphagia and emergency treatment markets Arbli and Rezenopy target, supports a favorable risk‑reward profile and justifies maintaining the $1.50 price target and Buy rating.